Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will compare the pharmacokinetics (PK) effect of two different formulations of Gecacitinib Hydrochloride Tablets in healthy Adult participants
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Test Group | Experimental | Participants will take a single Gecacitinib 75mg Tablet under fasting condition |
|
| Reference Group | Experimental | Participants will take a single Gecacitinib 75mg Tablet under fasting condition |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Gecacitinib Hydrochloride Tablets | Drug | Administered orally |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Plasma Concentration (Cmax) Of Gecacitinib and its main metabolite ZG0244 | up to 48 hours | |
| Gecacitinib and its main metabolite ZG0244 AUC(0-t) | up to 48 hours | |
| Gecacitinib and its main metabolite ZG0244 AUC(0-inf) | up to 48 hours |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jason Wu | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Third Hospital of Changsha | Changsha | Hunan | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided